<PAGE> 1
SECURITIES AND EXCHANGE COMMISSION
Washington, DC 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): February 26, 1998
QUINTILES TRANSNATIONAL CORP.
(Exact name of registrant as specified in its charter)
North Carolina 340-23520 56-1714315
(State or other (Commission File No.) I.R.S. Employer
jurisdiction Identification Number
of incorporation)
4709 Creekstone Drive
Riverbirch Building, Suite 200
Durham, North Carolina 27703-8411
(Address of principal executive offices)
(919) 941-2000
(Registrant's telephone number, including area code)
N/A
(Former name or former address, if changed since last report)
<PAGE> 2
Item 9. Sales of Equity Securities Pursuant to Regulation S
On February 26, 1998, Quintiles Transnational Corp. (the "Company")
completed the acquisition of T2A S.A., a French contract sales organization
("T2A"). The Company issued 311,899 shares of its Common Stock, par value $0.01
per share, in exchange for the interests of the holders of all of the
outstanding share capital of T2A, other than three dissenting shareholders
owning less than 0.03% of T2A who were paid cash. An aggregate of 109,166 shares
were issued in reliance on Regulation S and 202,733 shares were issued in
reliance on a claim of exemption pursuant to section 4(2) of the Securities Act
of 1933, as amended, based on representations made by the recipients in the
share acquisition agreement.
On February 27, 1998, Quintiles Transnational Corp. (the "Company")
completed the acquisition of More Biomedical Contract Research Organization
Ltd., a contract research organization based in Taiwan ("More Biomedical"). The
Company issued 16,600 shares of its Common Stock, par value $0.01 per share, to
the sole shareholder of More Biomedical in exchange for his interest. All of
such shares were issued in reliance on Regulation S based on representations
made by the recipient in the share sale agreement.
<PAGE> 3
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934,
the Registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
QUINTILES TRANSNATIONAL CORP.
By: /s/ Rachel R. Selisker
--------------------------
Dated: March 10, 1998 Rachel R. Selisker
Chief Financial Officer and Executive Vice
President Finance
